Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide/formoterol MDI with spacer versus Symbicort Turbuhaler in severe COPD with low inspiratory flow
2019-001801-26Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide and formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Peak change from baseline in FEV1 within 4 hours post-dose following 1 week of treatment. Started Jun 2019; status: completed.
02
Drugs
budesonideformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2019-001801-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001801-26.